Chesley Taft & Associates LLC Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Chesley Taft & Associates LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 1.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 148,607 shares of the biopharmaceutical company’s stock after selling 2,176 shares during the period. Chesley Taft & Associates LLC’s holdings in Pfizer were worth $4,301,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. FAS Wealth Partners Inc. grew its holdings in shares of Pfizer by 1.3% in the second quarter. FAS Wealth Partners Inc. now owns 26,306 shares of the biopharmaceutical company’s stock valued at $736,000 after purchasing an additional 342 shares in the last quarter. Sachetta LLC grew its stake in shares of Pfizer by 7.3% in the second quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 342 shares in the last quarter. Ironvine Capital Partners LLC grew its stake in shares of Pfizer by 2.1% in the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock worth $470,000 after acquiring an additional 353 shares in the last quarter. Secure Asset Management LLC raised its stake in shares of Pfizer by 0.6% in the second quarter. Secure Asset Management LLC now owns 58,328 shares of the biopharmaceutical company’s stock valued at $1,632,000 after acquiring an additional 353 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. boosted its holdings in Pfizer by 0.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock valued at $1,180,000 after purchasing an additional 355 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Finally, StockNews.com lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Up 2.1 %

PFE stock opened at $29.19 on Tuesday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $33.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market cap of $165.41 billion, a price-to-earnings ratio of -486.50, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. The company has a fifty day moving average price of $29.17 and a 200 day moving average price of $28.32.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.